Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about ALK: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Gene Symbol | ALK |
| Molecular Weight | 200 kDa |
| Pathways | PI3K, MAPK |
| GeneCards | ALK |
| Human Protein Atlas | ALK |
| Associated Diseases | ALS |
| Interactions | EGFR, IRF2BP2, KRAS, YAP |
| KG Connections | 18 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
ALK["ALK"]
NEUROBLASTOMA["NEUROBLASTOMA"]
ALK -->|"activates"| NEUROBLASTOMA
TUMOR_CELLS["TUMOR CELLS"]
TUMOR_CELLS -->|"regulates"| ALK
IRF2BP2["IRF2BP2"]
ALK -->|"activates"| IRF2BP2
ALK -->|"regulates"| IRF2BP2
APC["APC"]
ALK -->|"associated with"| APC
ARID1A["ARID1A"]
ALK -->|"associated with"| ARID1A
DNA["DNA"]
ALK -->|"associated with"| DNA
KRAS["KRAS"]
ALK -->|"associated with"| KRAS
TP53["TP53"]
ALK -->|"associated with"| TP53
NEUROBLASTOMA -->|"associated with"| ALK
style ALK fill:#0d47a1,stroke:#42a5f5,stroke-width:2px,color:#fff| Target | Relation | Type | Str |
|---|---|---|---|
| h-5d753df0 | targeted_by | hypothesis | 1.00 |
| NEUROBLASTOMA | activates | disease | 0.65 |
| EGFR | targets | gene | 0.60 |
| KRAS | targets | gene | 0.60 |
| cancer | targets | disease | 0.60 |
| EGFR | activates | gene | 0.60 |
| KRAS | activates | gene | 0.60 |
| YAP | activates | gene | 0.60 |
| cancer | activates | disease | 0.60 |
| IRF2BP2 | activates | gene | 0.60 |
| IRF2BP2 | regulates | gene | 0.60 |
| APC | associated_with | gene | 0.60 |
| ARID1A | associated_with | gene | 0.60 |
| DNA | associated_with | gene | 0.60 |
| KRAS | associated_with | gene | 0.60 |
| TP53 | associated_with | gene | 0.60 |
| ALS | associated_with | disease | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| h-5d753df0 | targets | hypothesis | 1.00 |
| 34819673 | is activated by | paper | 0.90 |
| TUMOR CELLS | regulates | cell_type | 0.65 |
| NEUROBLASTOMA | associated_with | disease | 0.45 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| TREM2 Agonist Antibody Rescue of Astrocyte-Microglia Signalling in 5xF | in_vivo | Alzheimer's disease | 0.794 | 0.72 | 5xFAD transgenic mice (n=15/gr | proposed | $85,000 |
| TREM2 R47H iPSC Co-culture Screen for A1 Astrocyte Polarisation Rescue | in_vitro | Alzheimer's disease | 0.788 | 0.75 | Human iPSC-derived astrocytes | proposed | $52,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Lifestyle Intervention Mechanisms in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $430,000 |
| MLCS Quantification in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Sirtuin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Sirtuin Pathway Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2- [PMID:31932797] | Zhou Y, Song WM, Andhey PS, Swain A, Lev | Nat Med | 2020 | 1 |
| Homoplantaginin ameliorates osteoarthritis by activating Sirt3/PINK1/Parkin sign [PMID:41720004] | Zhang H, Xiao J, Yi Y, Chen B, Lv W et a | Phytomedicine | 2026 | 0 |
| Kakkalide promotes spinal cord injury repair by regulating microglial M2 polariz [PMID:41720005] | You T, Dai B, Ding X, He Z, Peng J et al | Phytomedicine | 2026 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Emerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Thera [PMID:40922457] | ["Eroglu E", "Harmanci N"] | Basic & clinical pharmacology | 2025 | 0 |
| Microglia, Trem2, and Neurodegeneration. [PMID:38769824] | Shi Q, Gutierrez RA, Bhat MA | Neuroscientist | 2025 | 0 |
| Microglia, Trem2, and Neurodegeneration. [PMID:38769824] | Shi Q, Gutierrez RA, Bhat MA | The Neuroscientist : a review | 2025 | 0 |
| Mitochondrial dysfunction and aging: multidimensional mechanisms and therapeutic [PMID:40634825] | Wei P, Zhang X, Yan C, Sun S, Chen Z, Li | Biogerontology | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Bridging gap in the treatment of Alzheimer's disease via postbiotics: Current pr [PMID:39952328] | ["Bashir B", "Gulati M", "Vishwas S", "G | Ageing research reviews | 2025 | 0 |
| Serine synthesis sustains macrophage IL-1β production via NAD+-dependent protein [PMID:38266638] | Wang C, Chen Q, Chen S, Fan L, Gan Z, Zh | Molecular cell | 2024 | 0 |
| SIRT3-Mediated Deacetylation of SDHA Rescues Mitochondrial Bioenergetics Contrib [PMID:38087172] | ["Shen Y", "Wang X", "Nan N", "Fu X", "Z | Molecular neurobiology | 2024 | 0 |
| SIRT3: A potential therapeutic target for liver fibrosis. [PMID:38561088] | ["Ning Y", "Dou X", "Wang Z", "Shi K", " | Pharmacology & therapeutics | 2024 | 0 |
| The role of microglial TREM2 in development: A path toward neurodegeneration? [PMID:38837837] | ["Matteoli Michela"] | Glia | 2024 | 0 |
| TREM2 receptor protects against complement-mediated synaptic loss by binding to [PMID:37442133] | Zhong L, Sheng X, Wang W, Li Y, Zhuo R, | Immunity | 2023 | 0 |
| Sirtuin family in autoimmune diseases. [PMID:37483618] | Tao Z, Jin Z, Wu J, Cai G, Yu X | Frontiers in immunology | 2023 | 0 |
| Mitochondrial sirtuins, metabolism, and aging. [PMID:34856390] | Ji Z, Liu GH, Qu J | Journal of genetics and genomi | 2022 | 0 |
| Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegen [PMID:34151764] | Kumar V, Kundu S, Singh A, Singh S | Curr Neuropharmacol | 2022 | 0 |
| Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegen [PMID:34151764] | Kumar V, Kundu S, Singh A, Singh S | Current neuropharmacology | 2022 | 0 |
| FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic [PMID:36134579] | Jin L, Geng L, Ying L, Shu L, Ye K, Yang | Circulation | 2022 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning ALK in their description or question text
Score: 0.701 · neurodegeneration · 2026-04-02
## Mechanistic Overview Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration starts from the claim that modulating SI
Score: 0.680 · neurodegeneration · 2026-04-12
## Mechanistic Overview TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration starts from the claim that m
Score: 0.649 · developmental neurobiology · 2026-04-21
## **Molecular Mechanism and Rationale** The CX3CR1-mediated fractalkine signaling pathway represents a critical regula
Score: 0.642 · neurodegeneration · 2026-04-07
## **Molecular Mechanism and Rationale** The triggering receptor expressed on myeloid cells 2 (TREM2) serves as a criti
Score: 0.625 · neurodegeneration · 2026-04-07
**Molecular Mechanism and Rationale** The TREM2-mediated astrocyte-microglia cross-talk mechanism represents a complex
Score: 0.600 · neurodegeneration · 2026-04-25
MAP6 stability activity may suppress adjacent tau lability activity through direct physical interaction or by altering t
Score: 0.600 · neurodegeneration · 2026-04-21
## **Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) signaling pathway
Score: 0.587 · Alzheimer's disease · 2026-04-04
# Cardiovascular-Neuroinflammation Crosstalk Interruption: Targeting Shared Inflammatory Mediators in Neurodegeneratio
Score: 0.563 · neurodegeneration · 2026-04-02
## Mechanistic Overview Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim t
Score: 0.540 · neurodegeneration · 2026-04-22
## Mechanistic Overview Soluble CX3CL1 cleavage by ADAM proteases disengages fractalkine signaling, removing the neurona
Score: 0.530 · neurodegeneration · 2026-04-25
Combining NAC (GSH precursor/peroxynitrite scavenger) with ferrostatin-1 (specific ferroptosis inhibitor) provides dual
Score: 0.510 · neurodegeneration · 2026-04-22
## Mechanistic Overview Tripartite Synapse Cell Type-Nonautonomous Crosstalk: Coordinated Failure starts from the claim
Score: 0.470 · neuroinflammation · 2026-04-21
## Mechanistic Overview C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis starts from the claim that modulating C1QA
Score: 0.459 · immunomics · 2026-04-25
CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation